CD8highCD57+ T-cell population as an independent predictor of response to chemoradiation therapy in extensive-stage small cell lung cancer

Lung Cancer

Volumn 90, Issue 2, 2015, Pages 326-333

  Dobrovolskiene, Neringa T ^a,b   Cicenas, Saulius ^c   Kazlauskaite, Nijole ^c   Mišeikyte Kaubriene, Edita ^c   Krasko, Jan A ^a   Ostapenko, Valerijus ^c   Pašukoniene, Vita ^a   Strioga, Marius M ^a  

^a NATIONAL CANCER INSTITUTE   (Lithuania)

^b State Research Institute Centre for Innovative Medicine   (Lithuania)

^c NATIONAL CANCER INSTITUTE   (Lithuania)

Author keywords

CD8+CD57+ T cells; Immune profile; Predictive biomarkers; Small cell lung cancer

Indexed keywords

BIOLOGICAL MARKER; CD57 ANTIGEN; CD8 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PERFORIN; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; POPULATION; PREDICTIVE VALUE; PRIORITY JOURNAL; SMALL CELL LUNG CANCER; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE; CD8+ T LYMPHOCYTE; IMMUNOLOGY; LUNG NEOPLASMS; MIDDLE AGED; PROCEDURES; SMALL CELL LUNG CARCINOMA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CD8-POSITIVE T-LYMPHOCYTES; CHEMORADIOTHERAPY; FEMALE; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SMALL CELL LUNG CARCINOMA;

EID: 84955254663     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.08.001     Document Type: Article

References (56)

1. Govindan R., Page N., Morgensztern D., Read W., Tierney R., Vlahiotis A., Spitznagel E.L., Piccirillo J. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J. Clin. Oncol. 2006, 24(28):4539-4544.
2. Stamatis G. Neuroendocrine tumors of the lung: the role of surgery in small cell lung. Thorac. Surg. Clin. Cancer 2014, 24(3):313-326.
3. Ganti A.K., West W.W., Zhen W. Current concepts in the management of small cell lung cancer. Indian J. Med. Res. 2013, 137(6):1043-1051.
4. Lally B.E., Urbanic J.J., Blackstock A.W., Miller A.A., Perry M.C. Small cell lung cancer: have we made any progress over the last 25 years?. Oncologist 2007, 12(9):1096-1104.
5. Okuno S.H., Jett J.R. Small cell lung cancer: current therapy and promising new regimens. Oncologist 2002, 7(3):234-238.
6. Jett J.R., Schild S.E., Kesler K.A., Kalemkerian G.P. Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013, 143(Suppl. 5). e400S-19S.
7. Hall R.D., Gray J.E., Chiappori A.A. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control 2013, 20(1):22-31.
8. Parums D.V. Current status of targeted therapy in non-small cell lung cancer. Drugs Today (Barc.) 2014, 50(7):503-525.
9. Riess J.W., Lara P.N. Left behind? Drug discovery in extensive-stage small-cell lung cancer. Clin. Lung Cancer 2014, 15(2):93-95.
10. Characiejus D., Jacobs J.J., Pašukoniene V., Kazlauskaite N., Danilevičiute V., Mauricas M., Den Otter W. Prediction of response in cancer immunotherapy. Anticancer Res. 2011, 31(2):639-647.
11. Gajewski T.F., Louahed J., Brichard V.G. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. J. Cancer 2010, 16(4):399-403.
12. Roepman P., Jassem J., Smit E.F., Muley T., Niklinski J., van, de V., elde T., Witteveen A.T., Rzyman W., Floore A., Burgers S., Giaccone G., Meister M., Dienemann H., Skrzypski M., Kozlowski M., Mooi W.J., van Z., andwijk N. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin. Cancer Res. 2009, 15(1):284-290.
13. West N.R., Milne K., Truong P.T., Macpherson N., Nelson B.H., Watson P.H. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011, 13(6):R126.
14. Zitvogel L., Kepp O., Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat. Rev. Clin. Oncol. 2011, 8(3):151-160.
15. Anitei M.G., Zeitoun G., Mlecnik B., Marliot F., Haicheur N., Todosi A.M., Kirilovsky A., Lagorce C., Bindea G., Ferariu D., Danciu M., Bruneval P., Scripcariu V., Chevallier J.M., Zinzindohoué F., Berger A., Galon J., Pagès F. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin. Cancer Res. 2014, 20(7):1891-1899.
16. Shibuya K.C., Goel V.K., Xiong W., Sham J.G., Pollack S.M., Leahy A.M., Whiting S.H., Yeh M.M., Yee C., Riddell S.R., Pillarisetty V.G. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. PLoS One 2014, 9(5):e96565.
17. Kaufman H.L., Kim D.W., DeRaffele G., Mitcham J., Coffin R.S., Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol. 2010, (3):718-730.
18. Tjin E.P., Konijnenberg D., Krebbers G., Mallo H., Drijfhout J.W., Franken K.L., van, der H., orst C.M., Bos J.D., Nieweg O.E., Kroon B.B., Haanen J.B., Melief C.J., Vyth-Dreese F.A., Luiten R.M. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin. Cancer Res. 2011, 17(17):5736-5747.
19. Strioga M., Pasukoniene V., Characiejus D. CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunology 2011, 134(1):17-32.
20. Characiejus D., Pasukoniene V., Kazlauskaite N., Valuckas K.P., Petraitis T., Mauricas M., Den Otter W. Predictive value of CD8highCD57+ lymphocyte subset in interferon therapy of patients with renal cell carcinoma. Anticancer Res. 2002, 22(6B):3679-3683.
21. Characiejus D., Pasukoniene V., Jonusauskaite R., Azlauskaite N., Aleknavicius E., Mauricas M., Otter W.D. Peripheral blood CD8highCD57+ lymphocyte levels may predict outcome in melanoma patients treated with adjuvant interferon-alpha. Anticancer Res. 2008, 28(2B):1139-1142.
22. Jacobs J.J., Characiejus D., Pašukoniene V., Jankevicius F., Van Moorselaar R.J., Mauricas M., Den Otter W. Recurrences of superficial bladder carcinoma are associated with a rise of CD8highCD57+ and CD8low T lymphocytes in peripheral blood. Open Cancer Immunol. J. 2010, 3:8-14.
23. Characiejus D., Pasukoniene V., Jacobs J.J., Eidukevicius R., Jankevicius F., Dobrovolskiene N., Mauricas M., Van Moorselaar R.J., Den Otter W. Prognostic significance of peripheral blood CD8highCD57+ lymphocytes in bladder carcinoma patients after intravesical IL-2. Anticancer Res. 2011, 31(2):699-703.
24. Shevach E.M., Thornton A.M. tTregs, pTregs, and iTregs: similarities and differences. Immunol. Rev. 2014, 259(1):88-102.
25. Chattopadhyay P.K., Betts M.R., Price D.A., Gostick E., Horton H., Roederer M., De Rosa S.C. The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J. Leukoc. Biol. 2009, 85(1):88-97.
26. Figueiredo C., Seltsam A., Blasczyk R. Permanent silencing of NKG2A expression for cell-based therapeutics. J. Mol. Med. (Berl.) 2009, 87(2):199-210.
27. Ohkura N., Kitagawa Y., Sakaguchi S. Development and maintenance of regulatory T cells. Immunity 2013, 38(3):414-423.
28. Kapp J.A., Bucy R.P. CD8+ suppressor T cells resurrected. Hum. Immunol. 2008, 69(11):715-720.
29. Fenoglio D., Ferrera F., Fravega M., Balestra P., Battaglia F., Proietti M., Andrei C., Olive D., Antonio L.C., Indiveri F., Filaci G. Advancements on phenotypic and functional characterization of non-antigen-specific CD8+CD28- regulatory T cells. Hum. Immunol. 2008, 69(11):745-750.
30. Roncarolo M.G., Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells?. Eur. J. Immunol. 2008, 38(4):925-927.
31. Wilke C.M., Wu K., Zhao E., Wang G., Zou W. Prognostic significance of regulatory T cells in tumor. Int. J. Cancer 2010, 127(4):748-758.
32. Hasegawa T., Suzuki H., Yamaura T., Muto S., Okabe N., Osugi J., Hoshino M., Higuchi M., Ise K., Gotoh M. Prognostic value of peripheral and local forkhead box P3+ regulatory T cells in patients with non-small-cell lung cancer. Mol. Clin. Oncol. 2014, 2(5):685-694.
33. Bandrés E., Merino J., Vázquez B., Inogés S., Moreno C., Subirá M.L., Sánchez-Ibarrola A. The increase of IFN-gamma production through aging correlates with the expanded CD8(+high)CD28(-)CD57(+) subpopulation. Clin. Immunol. 2000, 96(3):230-235.
34. García-Muñoz R., Rodríguez-Otero P., Galar A., Merino J., Beunza J.J., Páramo J.A., Lecumberri R. Expansion of CD8+CD57+ T cells in an immunocompetent patient with acute toxoplasmosis. Adv. Hematol. 2009, 2009:173439.
35. Le Priol Y., Puthier D., Lécureuil C., Combadière C., Debré P., Nguyen C., Combadière B. High cytotoxic and specific migratory potencies of senescent CD8+CD57+ cells in HIV-infected and uninfected individuals. J. Immunol. 2006, 177(8):5145-5154.
36. Sada-Ovalle I., Torre-Bouscoulet L., Valdez-Vázquez R., Martínez-Cairo S., Zenteno E., Lascurain R. Characterization of a cytotoxic CD57+ T cell subset from patients with pulmonary tuberculosis. Clin. Immunol. 2006, 121(3):314-323.
37. Ohkawa T., Seki S., Dobashi H., Koike Y., Habu Y., Ami K., Hiraide H., Sekine I. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Immunology 2001, 103(3):281-290.
38. Pedroza-Seres M., Linares M., Voorduin S., Enrique R.R., Lascurain R., Garfias Y., Jimenez-Martinez M.C. Pars planitis is associated with an increased frequency of effector-memory CD57+ T cells. Br. J. Ophthalmol. 2007, 91(10):1393-1398.
39. Tsuda M., Ambrosini Y.M., Zhang W., Yang G.X., Ando Y., Rong G., Tsuneyama K., Sumida K., Shimoda S., Bowlus C.L., Leung P.S., He X.S., Coppel R.L., Ansari A.A., Lian Z.X., Gershwin M.E. Fine phenotypic and functional characterization of effector cluster of differentiation 8 positive T cells in human patients with primary biliary cirrhosis. Hepatology 2011, 54(4):1293-1302.
40. Frassanito M.A., Silvestris F., Cafforio P., Dammacco F. CD8+/CD57 cells and apoptosis suppress T-cell functions in multiple myeloma. Br. J. Haematol. 1998, 100(3):469-477.
41. Gorochov G., Debré P., Leblond V., Sadat-Sowti B., Sigaux F., Autran B. Oligoclonal expansion of CD8+CD57+ T cells with restricted T-cell receptor beta chain variability after bone marrow transplantation. Blood 1994, 83(2):587-595.
42. Sadat-Sowti B., Debré P., Mollet L., Quint L., Hadida F., Leblond V., Bismuth G., Autran B. An inhibitor of cytotoxic functions produced by CD8+CD57+ T lymphocytes from patients suffering from AIDS and immunosuppressed bone marrow recipients. Eur. J. Immunol. 1994, 24(11):2882-2888.
43. Joly P., Guillon J.M., Mayaud C., Plata F., Theodorou I., Denis M., Debre P., Autran B. Cell-mediated suppression of HIV-specific cytotoxic T lymphocytes. J. Immunol. 1989, 143(7):2193-2201.
44. Wang E.C., Taylor-Wiedeman J., Perera P., Fisher J., Borysiewicz L.K. Subsets of CD8+, CD57+ cells in normal, healthy individuals: correlations with human cytomegalovirus (HCMV) carrier status, phenotypic and functional analyses. Clin. Exp. Immunol. 1993, 94(2):297-305.
45. Akagi J., Baba H. Prognostic value of CD57(+) T lymphocytes in the peripheral blood of patients with advanced gastric cancer. Int. J. Clin. Oncol. 2008, 13(6):528-535.
46. Mileshkin L., Honemann D., Gambell P., Trivett M., Hayakawa Y., Smyth M., Beshay V., Ritchie D., Simmons P., Milner A.D., Zeldis J.B., Prince H.M. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome. Haematologica 2007, 92(8):1075-1082.
47. Akagi J., Baba H. PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients. Int. J. Clin. Oncol. 2010, 15(2):145-152.
48. Elliott G.T., McLeod R.A., Perez J., Von Eschen K.B. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin. Surg. Oncol. 1993, 9(3):264-272.
49. Wang W., Hodkinson P., McLaren F., MacKinnon A., Wallace W., Howie S., Sethi T. Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate. Int. J. Cancer 2012, 131(6):E928-E937.
50. Tosolini M., Kirilovsky A., Mlecnik B., Fredriksen T., Mauger S., Bindea G., Berger A., Bruneval P., Fridman W.H., Pagès F., Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011, 71(4):1263-1271.
51. Aruga T., Suzuki E., Saji S., Horiguchi S., Horiguchi K., Sekine S., Kitagawa D., Funata N., Toi M., Sugihara K., Kuroi K. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. Oncol. Rep. 2009, 22(2):273-278.
52. Billerbeck E., Nakamoto N., Seigel B., Blum H.E., Chang K.M., Thimme R. Determinants of in vitro expansion of different human virus-specific FoxP3+ regulatory CD8+ T cells in chronic hepatitis C virus infection. J. Gen. Virol. 2009, 90(Pt 7):1692-1701.
53. Den Otter W., Van Moorselaar R.J., Jacobs J.J., Haar R.T., Koten J.W., Dobrowolski Z., Lipczynski W., Pašukoniene V., Characiejus D., Jankevičius F., Eidukevičius R., De Reijke T.M. Role of marker lesion when applying intravesical instillations of IL-2 for non-muscle-invasive bladder cancer comparison of the therapeutic effects in two pilot studies. Anticancer Res. 2013, 33(5):2099-2105.
54. Stoll G., Bindea G., Mlecnik B., Galon J., Zitvogel L., Kroemer G. Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies. Oncotarget 2015, 6(14):11894-11909.
55. Jeremic B., Shibamoto Y., Nikolic N., Milicic B., Milisavljevic S., Dagovic A., Aleksandrovic J., Radosavljevic-Asic G. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J. Clin. Oncol. 1999, 17(7):2092-2099.
56. Slotman B.J., van Tinteren H., Praag J.O., Knegjens J.L., El Sharouni S.Y., Hatton M., Keijser A., Faivre-Finn C., Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 2015, 385(9962):36-42.